To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.

US Ophthalmic Review Highlights A Novel Avastin Injection Technique—“Sunalp Protocol” Direct Visualization Delivery of Bevacizumab in Pseudophakic Eyes for the Treatment of Subretinal Neovascularization Murad A Sunalp, MD, MBA, FACS, 1 Lindsey B Buchbinder BS, MPH 2 and Myhidin H Shehu, MD, MBA 3 1. President, Sunalp Laser Vision, Tulare, California, US; 2. Medical Student, St George’s University, True Blue, Grenada; 3. Medical Director, Sunalp Laser Vision, Tulare, California, US Abstract Purpose: The introduction of vascular endothelial growth factor (VEGF) inhibitors began a new era in the treatment of exudative age-related macular degeneration (ARMD). These drugs are effective at suppressing choroidal neovascularization (CNV) resulting in improvement or stabilization of visual acuity; however, the chronic nature of the disease require these drugs be administered periodically (usually monthly) for the life of the patient. Since intravitreal injections are administered through the sclera, there is the possibility of adverse events, such as vitreous hemorrhage, endophthalmitis, retinal tears, or retinal detachment. To avoid some of the adverse events associated with intravitreal delivery via the scleral route we have developed a technique to deliver bevacizumab (Avastin ® ) into the vitreous cavity in pseudophakic eyes via a corneal route. Methods: A 27-gauge, 5 mm angled cannula attached to a 1.0 ml syringe is fitted into an 11 o’clock limbal incision and advanced through the anterior and posterior chamber. The cannula is maneuvered through the zonules into the vitreous and 0.1 ml of Avastin is delivered behind the lens into the vitreous cavity. The procedure was performed in 50 eyes (Addendum 1: 499 injections 2014–2015), of five exudative ARMD patients, 21 diabetic macular edema (DME) patients, two cystoid macular edema (CME) patients, and one central retinal vein occlusion (CRVO) patient. Visual acuity (VA), edema, optical coherence tomography (OCT), and endothelial cell counts were performed 1 day following Avastin administration. VA was also determined in 16 eyes at 1 month after Avastin administration. Results: At 1 day post-Avastin administration, vision acuity and edema index improved or remained stable in all eyes, with the exception of one eye from an exudative ARMD patient whose vision deteriorated. At 1 month the average visual acuity in 16 eyes was also significantly improved. The improvement in edema was evident through retinal OCTs. No change in endothelial cell counts was observed. Conclusions: Administration of Avastin via an anterior chamber route in pseudophakic (Addendum 2: Phakic eyes were also treated with no cataract formation) patients is effective for the treatment of exudative ARMD, DME, CME and CRVO, minimizing the possible adverse events related to the administration by the traditional scleral route. In addition, anterior segment administration allows the ophthalmologist to directly observe the delivery of the drug with microscope precision. Pars plana injections are usually performed without magnification and no direct visualization. Keywords Age-related macular degeneration, anterior segment, bevacizumab, choroidal neovascularization, diabetic macular edema, pseudophakic, Sunalp protocol Disclosure: Murad A Sunalp, MD, MBA, FACS, Lindsey B Buchbinder BS, MPH, and Myhidin H Shehu, MD, MBA, have no conflicts of interest to declare. No funding was received in the publication of this article. A Novel Avastin injection technique “Sunalp Protocol” was first presented by Murad A Sunalp, MD, MBA, FACS, at ASCRS, San Diego, California in March 26, 2011. Compliance with Ethics Guidelines: All procedures were followed in accordance with the responsible committee on human experimentation and with the Helsinki Declaration of 1975 and subsequent revisions, and informed consent was received from the patients involved in this study. Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit. Received: June 10, 2015 Accepted: September 3, 2015 Citation: US Ophthalmic Review, 2015;8(2):118–24 Correspondence: Murad A Sunalp, MD, MBA, FACS, Sunalp Laser Vision, 880 E Merritt Ave, Suite109, Tulare, CA 93274, US. E: Supplementary Information: An accompanying video to this article can be found at In 2006, the US Food and Drug Administration (FDA) approved Genentech’s ranibizumab (Lucentis ® ), a Fab fragment of a humanized monoclonal anti-vascular endothelial growth factor (VEGF)-A designed for intraocular use for the treatment of exudative age-related macular degeneration (ARMD). Since 2006, ranibizumab and its parent monoclonal antibody bevacizumab have been extensively used to TOU CH MED ICA L MEDIA treat exudative ARMD. Intravitreal injections of bevacizumab and ranibizumab have become the most common treatment for exudative ARMD resulting in visual stabilization in 90  % of patients and a gain of 3 or more lines of visual acuity (VA) in 30–40  % of the patients. 1–3 Even though the development of inhibitors of VEGF has transformed the treatment of exudative ARMD and other ocular neovascular 169